Acucela Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH130932D
- Pages: 22
- September 2018
- Total Views:1126
- Region : North America
- GlobalData
- Equity Research Report

Details
Summary
Acucela Inc (Acucela), a subsidiary of Kubota Pharmaceutical Holding is a developer of treatments for degenerative eye diseases and pharmaceutical compound screening system. The company develops its products using its visual cycle modulation technology. It offers emixustat hydrochloride which is used for geographic atrophy secondary and releated dry age-related macular degeneration. The company's drug candidates are intended for the treatment of geographic atrophy, proliferative diabetic retinopathy, retinitis pigmentosa, cataract, and glaucoma. It develops drugs and devices to preserve and restore vision. Acucela is headquartered in Seattle, Washington, the US.
Acucela Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acucela Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Acucela Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Acucela Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Acucela Enters into Development Agreement with EyeMedics 10
Licensing Agreements 11
Acucela Enters into Licensing Agreement with University of Manchester 11
Acucela Enters into Option Agreement with YouHealth Eyetech 12
Equity Offering 14
Acucela Raises USD162.4 Million in IPO 14
Acucela Inc-Key Competitors 15
Acucela Inc-Key Employees 16
Acucela Inc-Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Product Approvals 18
Jan 05, 2017: Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease 18
Clinical Trials 19
Jun 21, 2018: New Acucela Data on the Effect of Emixustat Hydrochloride on Retinal Thickness in Diabetic Retinopathy 19
Sep 10, 2017: Acucela Receives New Patent Covering Method of Use for Emixustat Hydrochloride 20
Jan 26, 2017: Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt Disease 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22
List Of Figure
List of Figures
Acucela Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acucela Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List Of Table
List of Tables
Acucela Inc, Pharmaceuticals & Healthcare, Key Facts 2
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acucela Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acucela Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Acucela Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Acucela Enters into Development Agreement with EyeMedics 10
Acucela Enters into Licensing Agreement with University of Manchester 11
Acucela Enters into Option Agreement with YouHealth Eyetech 12
Acucela Raises USD162.4 Million in IPO 14
Acucela Inc, Key Competitors 15
Acucela Inc, Key Employees 16
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Acucela Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Acucela Inc (Acucela), a subsidiary of Kubota Pharmaceutical Holding is a developer of treatments for degenerative eye diseases and pharmaceutical compound screening system. The company develops its products using its visual cycle modulation technology. It offers emixustat hydrochloride which is used for geographic atrophy secondary and releated dry age-related macular degeneration. The company's drug candidates are intended for the treatment of geographic atrophy, proliferative diabetic retinopathy, retinitis pigmentosa, cataract, and glaucoma. It develops drugs and devices to preserve and restore vision. Acucela is headquartered in Seattle, Washington, the US.
Acucela Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acucela Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Acucela Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Acucela Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Acucela Enters into Development Agreement with EyeMedics 10
Licensing Agreements 11
Acucela Enters into Licensing Agreement with University of Manchester 11
Acucela Enters into Option Agreement with YouHealth Eyetech 12
Equity Offering 14
Acucela Raises USD162.4 Million in IPO 14
Acucela Inc-Key Competitors 15
Acucela Inc-Key Employees 16
Acucela Inc-Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Product Approvals 18
Jan 05, 2017: Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease 18
Clinical Trials 19
Jun 21, 2018: New Acucela Data on the Effect of Emixustat Hydrochloride on Retinal Thickness in Diabetic Retinopathy 19
Sep 10, 2017: Acucela Receives New Patent Covering Method of Use for Emixustat Hydrochloride 20
Jan 26, 2017: Acucela Initiates Phase 2a Study of Emixustat Hydrochloride Addressing Patients with Stargardt Disease 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22
List Of Figure
List of Figures
Acucela Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acucela Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List Of Table
List of Tables
Acucela Inc, Pharmaceuticals & Healthcare, Key Facts 2
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Acucela Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Acucela Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Acucela Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Acucela Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Acucela Enters into Development Agreement with EyeMedics 10
Acucela Enters into Licensing Agreement with University of Manchester 11
Acucela Enters into Option Agreement with YouHealth Eyetech 12
Acucela Raises USD162.4 Million in IPO 14
Acucela Inc, Key Competitors 15
Acucela Inc, Key Employees 16
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Acucela Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.